Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 1:05 pm Sale | 2024-09-30 | 13G | CalciMedica, Inc. CALC | Laurence W. Lytton | 468,943 4.400% | -287,237 (-37.99%) | Filing History |
| 2024-11-14 1:03 pm Purchase | 2024-09-30 | 13G | Acutus Medical, Inc. AFIB | Laurence W. Lytton | 2,078,030 7.000% | 331,207 (+18.96%) | Filing History |
| 2024-11-14 12:59 pm Sale | 2024-09-30 | 13G | Duos Technologies Group, Inc. DUOT | Laurence W. Lytton | 400,568 5.200% | -82,408 (-17.06%) | Filing History |
| 2024-11-14 12:56 pm Sale | 2024-09-30 | 13G | Azitra, Inc. AZTR | Laurence W. Lytton | 0 0.000% | -55,553 (Position Closed) | Filing History |
| 2024-10-23 7:40 pm Sale | 2024-09-30 | 13G | Creative Realities, Inc. CREX | Laurence W. Lytton | 784,000 7.500% | -268,204 (-25.49%) | Filing History |
| 2024-10-23 7:39 pm Purchase | 2023-12-31 | 13G | Creative Realities, Inc. CREX | Laurence W. Lytton | 1,052,204 10.100% | 11,000 (+1.06%) | Filing History |
| 2024-10-23 7:38 pm Purchase | 2023-12-04 | 13G | Creative Realities, Inc. CREX | Laurence W. Lytton | 1,041,204 10.000% | 41,204 (+4.12%) | Filing History |
| 2024-10-23 7:37 pm Purchase | 2023-08-18 | 13G | Creative Realities, Inc. CREX | Laurence W. Lytton | 1,000,000 9.600% | 1,000,000 (New Position) | Filing History |
| 2024-10-04 5:14 pm Purchase | 2024-09-26 | 13G | MDxHealth SA MDXH | Laurence W. Lytton | 2,890,595 6.100% | 2,890,595 (New Position) | Filing History |
| 2024-07-22 3:20 pm Purchase | 2024-07-10 | 13G | TELA Bio, Inc. TELA | Laurence W. Lytton | 1,340,052 5.400% | 1,340,052 (New Position) | Filing History |
| 2024-07-08 12:48 pm Purchase | 2024-06-27 | 13G | CalciMedica, Inc. CALC | Laurence W. Lytton | 756,180 6.900% | 756,180 (New Position) | Filing History |
| 2024-05-17 5:20 pm Purchase | 2024-05-09 | 13G | Acutus Medical, Inc. AFIB | Laurence W. Lytton | 1,746,823 5.900% | 1,746,823 (New Position) | Filing History |
| 2024-04-29 2:34 pm Purchase | 2024-04-17 | 13G | scPharmaceuticals Inc. SCPH | Laurence W. Lytton | 1,825,234 5.100% | 1,825,234 (New Position) | Filing History |
| 2024-03-20 1:00 pm Purchase | 2024-02-20 | 13G | Biofrontera Inc. BFRI | Laurence W. Lytton | 508,886 9.990% | 508,886 (New Position) | Filing History |
| 2024-03-13 1:32 pm Purchase | 2024-02-09 | 13G | Evoke Pharma, Inc. EVOK | Laurence W. Lytton | 71,610 9.990% | 71,610 (New Position) | Filing History |
| 2024-02-27 2:05 pm Purchase | 2024-02-14 | 13G | Azitra, Inc. AZTR | Laurence W. Lytton | 55,553 5.800% | 55,553 (New Position) | Filing History |
| 2024-02-14 6:48 pm Sale | 2023-12-31 | 13G | TFF Pharmaceuticals, Inc. TFFP | Laurence W. Lytton | 11,900 0.100% | -113,129 (-90.48%) | Filing History |
| 2024-02-14 3:28 pm Purchase | 2023-12-31 | 13G | Scientific Industries, Inc. SCND | Laurence W. Lytton | 1,083,899 9.990% | 689,220 (+174.63%) | Filing History |
| 2024-02-14 3:23 pm Purchase | 2023-12-31 | 13G | Cellectar Biosciences, Inc. CLRB | Laurence W. Lytton | 3,280,178 9.990% | 1,395,105 (+74.01%) | Filing History |
| 2024-02-14 2:42 pm Purchase | 2023-12-31 | 13G | Exagen Inc. XGN | Laurence W. Lytton | 1,153,488 6.800% | 282,307 (+32.41%) | Filing History |